
clariti commerci model
remdesivir upgrad hold
rais pt
model remdesivir sale vs credit base
base epi model market dynam firesid chat w/gild
management upgrad hold rais pt b/
 see potenti commerci sale near-term remdesivir
approv drug eua treat hospit covid patient model sale
base proprietari epi model w/strh dse team assum hospit
rate declin resurg earli assum
reason given cost save model ww sale
note sale everi add treatment add
dcf
upgrad rate hold sell increas pt
see clariti around potenti revenu
remdesivir report lay increas confid commerci
potenti remdesivir hospit patient note
us far alreadi hospit assumpt
base case assum ww sale
ramp declin use strh
proprietari epi model strh dse team price assumpt
base compar drug price iv rapivab tamiflu icer
price analysi industri kol check potenti govern demand ex-
us territori scenario analysi includ differ case
risk uncertainti around commerci remdesivir
base strh life scienc summit call cfo andi dickinson
diana brainard senior vice presid virolog area
head learn could gener commerci revenu
donat suppli run management assum june/juli
latest note compani said first phase address
immedi need second phase suppli govern interest
stockpil futur pandem
sell hold
tr target
given potenti commerci model urgent need address hospit patient
use proprietari strh dse data model us demand
base model take account season demand could
note resurg
granular individu countri hospit rate assum factor
base us hospit rate make assumpt potenti demand throughout year
remind sinc march us hospit patient
cost address patient us also could see global
govern contract treatment blend price
believ demand throughout govern address immedi
need prepar stockpil futur pandem
believ remdesivir may multi-year revenu stream conserv
assum sale beyond note addit treatment vaccin could approv
base case assum global sale vs foa
consensu
model base case assum global sale vs
prior model previous lack clariti remdesivir could gener revenu
report also note invest made toward manufactur clinic trial
addit opex remdesivir follow convers management speak kol
develop epi model increas confid potenti gener revenu
near-term donat suppli util howev note potenti on-going donat
may off-set sale increas cog sale everi addit annual treatment
remdesivir add dcf
risk treatment vaccin approv near-term may off-set potenti need
futur stockpil clinic risk remdesivir show benefit moder patient
data pend end may viru disappear resurg expect
catalyst part studi moder patient treat remdesivir vs soc expect
end may filgotinib ra expect
page
hold pt remdesivir could add revenu
page
pm summari initi hold pt
upgrad hold sell increas pt see clariti around
potenti sale remdesivir strh life scienc summit call cfo andi dickinson
diana brainard senior vice-president virolog area head learn could gener commerci sale
donat suppli run management assum june/juli latest report lay
increas confid commerci potenti remdesivir hospit patient
note us far alreadi hospit
base case assum ww sale ramp declin
use strh proprietari epi model strh dse team price assumpt
base compar drug price iv rapivab tamiflu icer price analysi industri kol
check potenti govern demand ex-u territori
includ differ scenario base case use proprietari epi model strh dse account
season estim immedi need address hospit patient near-term
granular individu countri hospit rate assum factor base us hospit rate
make assumpt potenti demand throughout year believ demand
throughout govt address immedi need prepar stockpil futur
pandem believ remdesivir may multi-year revenu stream conserv
assum sale beyond note treatment vaccin could approv
note key risk uncertainti around commerci remdesivir potenti treatment
vaccin could approv near-term may off-set requir stockpil need clinic risk
studi moder patient viru disappear resurg expect
model ww sale note sale everi add
treatment per year add dcf
catalyst part studi moder patient treat remdesivir vs soc expect end may
filgotinib ra expect
page
management commentari strh life scienc summit
much donat us
commit donat vial treatment cours depend patient
need vial vial
japan gave emerg approv remdesivir donat japan suppli
distribut us government includ vial donat
suppli donat run us
june juli latest
charg distribut remdesivir
strh life scienc call andi dickinson cfo said point move
tradit model back charg distribut global basi
unclear happen
andi also said govern continu overse distribut work
minimum hand-in-hand govern like rest year
toward end year like move tradit distribut
model gilead run independ
page
management commentari strh life scienc summit
global suppli
commit make drug access patient statement said sever
deal us govern govern potenti indirectli us government
note first phase address immedi need second phase suppli drug
govern interest stockpil futur pandem
us government lead ramp suppli point take lead global
short run manag us govern suppli ramp point
suppli equal demand suppli exce demand would expect see transit back
govern input assist guidanc overse distribut
system gilad take lead product deepli
commit provid access drug global
next year gener expect your sell govern way
anoth either whether assist us govern whether gild
directli tradit commerci model even us realli your sell
govern distribut popul
convers ir post-don work close govern healthcar
system provid access healthcar provid prescrib remdesivir appropri patient
page
management commentari strh life scienc summit
donat remdesivir suppli distribut hospit
us government coordin distribut base two thing
epidemiolog data sever diseas
need outbreak worst need roll week week basi
rest distribut led us government suppli ramp
may hh issu press releas initi shipment donat suppli remdesivir
page
management commentari strh life scienc summit
much remdesivir make
hope run rate treatment cours per month process
improv suppli chain
initi get cours patient would get vial assum cours
could get assum blend
expect usag littl bit less vial per patient gild assumpt current blend
averag vials/treat
note non-exclus licens agreement gener maker cipla cipla ns nr
gilbert buy base india pakistan agreement manufactur
remdesivir distribut countri set price gener product
licens agreement allow gener maker receiv technolog transfer
licens royalty-fre declar end public health emerg
page
commerci revenu could set stone
price
point charg cost fair market valu outsid pandem
transit donat model commerci model like donat suppli run
june/juli
donat model fair assum commerci revenu yet
set stone
formal price discuss happen data moder patient
icer analysi base case assum price view think low given potenti
cost save andi dickinson cfo note cost save four day icu
ten thousand dollar
govern use pay product similar circumst cost
view assum per treatment cours regardless treatment
page
spent remdesivir
much cost make remdesivir
least manufactur side togeth clinic trial cost
cost manufactur clinic trial
know spent manufactur scale-up clinic trial cost
 expens three month end march increas million compar
period primarili due ramp remdesivir includ approxim
million manufactur scale-up clinic trial cost partial off-set lower clinic trial
expens result paus postpon clinic trial result pandem
due pandem review clinic trial on-going research determin
continu fulli enrol trial temporarili postpon new trial paus enrol
trial result expect reduct clinic develop expens short-term
least partial off-set addit invest remdesivir includ develop
manufactur scale-up cost magnitud invest remdesivir depend
continu evolut data durat pandem factor invest
could billion primarili compris manufactur scale-up cost
account treatment invest depend upon number factor includ
hit sg cog account
 assum addit spend clinic trial on-going assum cog
toward scale-up simplic
page
shelf-lif remdesivir lyophil solut
govern stockpil shelf-lif remdesivir
remdesivir lyophil formul avail remdesivir inject mg remdesivir
inject mg stabl five year store room temperatur
remdesivir solut formul avail remdesivir inject mg/ml stabl two
year store refriger
believ govern stockpil need address immedi
certain hotspot declin daili incid countri like brazil
continu see increas
page
key question
far infect million kill
data collect john hopkin univers show us prepar stockpil futur
pandem expect anoth pandem winter much
us purchas
commerci contract govern look like
would price set certain rang base margin
multi-year contract stockpil futur outbreak
donat model current address immedi urgent need eua us
japan govern announc eua
govern stockpil futur
much countri need assess much purchas
price across nation
expect on-going donat certain countri
page
tidbit prior pandem government contract could look like
rapivab approv fda decemb treatment acut uncompl influenza
patient symptomat two day biocryst nr suppli rapivab
specialti distributor outlicens compani approv commerci avail
rapivab stock-pil procur contract govern
pandem suppli cours rapivab contract procur
cdc award biocryst nr million contract procur
dose biocryst approv antivir influenza therapi rapivab peramivir inject five-year
come per dose cost compar wac dose
could see barda stockpil contract price wac
sell rapivab specialti distributor sell physician offic hospit state commerci
statutori rebat medicaid medicar base statutori discount rapivab
gain clariti discuss healthcar system base prior experi
rapivab could see rebat discount remdesivir medicaid/medicar patient longer-
page
base strh dse team epi model expect season peak winter
believ epi data help drive decis make addit purchas stockpil use epi model
project us incid conduct scenario analysi incorpor data help
project futur need remdesivir see scenario analysi
use fit singl glm growth model exist data model could happen futur
one mani model model expect occur winter earli spring discount
account exist immun better hospit emerg servic manag better understand
sign symptom
chose much confirm case drop high
exercis discount curv key assumpt see season
recurr season recurr fraction current pandem continu
declin magnitud
note one
read
point estim rather
overal distribut
period time
magnitud time
still unknown
make assumpt
page
assumpt cog like improv economi scale
assum spent remdesivir cost toward manufactur
around million cours ye arriv per cost treatment
time along opex could see margin improv rang
depend sever factor includ price mani treatment donat
page
spent treatment ye manuf inc
assumpt price assum cours
price assum cours assum also note potenti
account discount hospitals/healthcar system
note icer low cost save day icu ten
thousand dollar price per cfo commentari
believ contract price could cheaper also assum price could come
time think economi scale much suppli make
also believ could high certain govern assum
discount certain countri see scenario
thing note
icer report note healthcar cost icu visit ventil
assum stay healthcar cost icu visit ventil stay
tamiflu record global sale pandem
thu believ cours unreason base cost save rel
drug market pandem situat
page
estim cost per treatment also expect continu make
donat remdesivir make assumpt on-going donat
assum on-going clinic trial expens note work
inhal formul remdesivir well on-going combo trial
hit sg cog account
assum addit spend clinic trial on-going assum cog toward scale-up simplic
model assum potenti treatment vaccin
believ less urgent need hospit patient
page
assumpt assumpt consider
assum us charg distribut remdesivir
assum take lead global distribut suppli per cfo
say us government could contract distribut hh state distribut
hospit note cfo said govern pay cost pandem
also believ could approv treatment hold
kevzara vaccin nr
base kol discuss epidemiolog data assum lower incid
case expect sharp increas winter month
note scenario base epi data need/demand
view believ near-term govern address immedi need
treat patient approv drug vaccin least
could see potenti stockpil see declin incid hospit rate
howev visibl govern give emerg approv
remdesivir yet outsid japan
also know much govern stockpil remdesivir view
govern stockpil proport burden current pandem
note gener maker out-licens visibl abil make drug
near-term on-lin yet expand gild suppli meet need region
page
scenario analysi remdesivir sale
scenario bear case base imh estim fv
scenario strh epi model stockpil assumpt fv
scenario stockpil assumpt base gild suppli fv
scenario maintain on-going rate incid hospit fv
page
scenario bear case assumpt seek remdesivir procur
page
page
use ihm epi data us note potenti season epi given potenti cost
number live affect thu far could see main buyer remdesivir
assum cost/treat across see need address immedi despit lower
incid summer near-term need winter base epi data believ
may need potenti prepar resurg
believ incid lower summer expect uptick winter month
assum infect hospit hospit assum icu
admit assign moder patient receiv remdesivir severe/icu
patient receiv remdesivir
assum treatment util contract donat
data base model us extrapol hospit data visibl japan us
eua assum patient treat remdesivir cours donat
includ initi donat april
assum us want contract remdesivir address immedi need
could expect want purchas remdesivir winter season expect
resurg could potenti stockpil time address current need
bear case assum price cours base epidemiolog data
ex-u contracts/stockpil assum blend price cours account
discount govern agenic us also note believ
medicaid/medicar statutori rebat payer discount occur assum discount
account on-going stockpil lower incid
page
scenario base case use proprietari epi model w/strh dse team
page
scenario base includ data proprietari epi model
page
scenario base assumpt includ epi data address immedi need
use strh proprietari dse team epi data us assum stockpil govern
factor us repres global case
us assum case declin us government continu provid drug address
immedi base epidemiolog data believ incid lower summer expect
uptick winter month assum infect hospit
hospit admit icu remdesivir use treat hospit patient
assum treatment purchas potenti anoth treatment may
donat addit treatment donat april data base model us
extrapol hospit data visibl japan us approv
assum patient treat remdesivir cours donat includ initi
donat april
given clariti around eua countri assum government contract
immedi urgent need stockpil make assumpt on-going contracts/stockpil
donat
assum price cours base epidemiolog data ex-u
contracts/stockpil assum blend price cours account
discount us also note believ medicaid/medicar statutori
rebat payer discount occur
assum constant contract ex-u season vari countri northern
hemispher summer could expect case south america continu increas
could see addit donat on-going
howev also assum addit treatment vaccin could approv addit
account measur
page
page
page
use assum stockpil scenario assum gener cours note
guid capac make cours per month make assumpt
cours contract mean pay cours anoth
cours donat
given clariti around eua countri assum government contract
immedi urgent need stockpil make assumpt on-going contracts/stockpil
donat
model assum treatment govern stockpil
note sinc march us cumul hospit patient thu
comparison perspect could see govern stockpil proport hospit burden
seen
assum price cours base epidemiolog data ex-u
contracts/stockpil assum blend price cours account
discount us also note believ medicaid/medicar statutori
rebat payer discount occur
assum constant contract ex-u season vari countri northern
hemispher summer could expect case south america continu increas
could see addit donat on-going
assum reduct purchas remdesivir account better handl diseas
public health measur treatment vaccin becom avail stockpil govern
page
page
us summari shown
page
use potenti market potenti buyer remdesivir near-term assum
incid juli remain constant scenario also assum treatment vaccin
assum could get assum blend scenario assum
cours would suppli treatment plu anoth treatment donat
given clariti around eua countri assum government contract
immedi urgent need stockpil make assumpt on-going contracts/stockpil
donat
assum price cours brazil per treatment
ex-u contracts/stockpil assum blend price cours account
discount us also note believ medicaid/medicar statutori
rebat payer discount occur brazil emerg market assum
assum constant contract purchas ex-u season vari countri
northern hemispher summer could expect case south america
continu increas could see addit donat on-going
page
page
incom revenu hiv us us jak product revenu incom contract oper expens exclud itemsgain loss secur interest incom incom exc spec provis loss attribut non-controlling interest net ep ep chang non- option expens pre provis tax net ep ep share share gilead scienc inc
inc biopharmaceut compani engag research develop
commerci medicin area unmet medic need primari area focu includ
oncolog inflamm respiratori diseas offer antivir product harvoni
vosevi brand compani found michael riordan june
headquart foster citi ca
gilead larg cap biotech compani construct entir new manag
team helm believ base hiv busi think offer stabl
revenu time think stock associ sentiment around remdesivir
visibl commerci remdesivir fundament growth
environ howev believ still commerci risk wait upcom data
moder patient beyond remdesivir think difficult see upsid name
see grow busi also believ investor get greater clariti
growth valuat like return fundament rate hold
valuat risk
pt deriv use probabl adjust dcf use discount rate appropri
larg cap stage biotech pipelin uncertainti assign share descovi prep
probabl peak sale filgotinib
risk rate price target includ upsid risk includ greater expect uptak
filgotinib greater convers biktarvi better expect commerci remdesivir
downsid risk includ commerci clinic trial risk remdeisvir
analyst elect benchmark perform rate stock subject
report
compani mention note
robyn karnauska herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
sandi balkin herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
page
